NCT07199413View on ClinicalTrials.gov

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

April 1, 2029

Study Completion Date

April 1, 2029

Conditions
Brain MetastasesLeptomeningeal Metastasis
Interventions
BIOLOGICAL

SV-BR-1-GM Vaccine

\~20 X 10\^6 cells across 4 injection sites

DRUG

Cyclophosphamide

300 mg/m\^2 Intravenous

DRUG

Pembrolizumab

200 mg/m\^2 Intravenous

DRUG

Interferon

0.18 mcg subcutaneous

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER